Read more

Gilead Sciences signed a deal for remdesivir.

1:31 PM 13 May 2020

Gilead Sciences (GILD.US)   announced that it had struck a licensing agreement to produce the antiviral drug remdesivir in 127 countries, not including the US. The company’s will work with five generic drugmakers to produce the potential drug for coronavirus. Among them is Mylan (MYL.US), which is the world's largest producer of generic drugs.


Gilead Sciences (GILD.US)  shares rose 1.96% in pre-market trading. If positive mood persists, then resistance at $86.16 per share may be tested. Source: xStation5

Share:
Back

Market News

30.06.2025
09:56

Chart of the day - USDIDX (30.06.2025)

The U.S. dollar is hovering near multi-year lows, testing key support levels around 97.0000 Weak data on personal income and consumer spending, along...

 08:05

Economic calendar: A calm start to the important week 📃

Markets are starting the new week with gains in U.S. futures and a moderately calm session across the European continent. Investors are awaiting trade...

 07:03

BREAKING: UK GDP in line with expectations 🎯

07:00 AM BST, United Kingdom - GDP data: GDP (Q1): actual 0.7% QoQ; forecast 0.7% QoQ; previous 0.1% QoQ; GDP (Q1): actual 1.3%...
More news

Join over 1 600 000 XTB Group Clients from around the world

Start trading Download the app Download the app
The financial instruments we offer, especially CFDs, can be highly risky. Fractional Shares (FS) is an acquired from XTB fiduciary right to fractional parts of stocks and ETFs. FS are not a separate financial instrument. The limited corporate rights are associated with FS.
This page was not created for investors residing in Brazil. This brokerage is not authorized by the Comissão de Valores Mobiliários (CVM) or the Brazilian Central Bank (BCB). The content of this page should not be characterized as an investment offer in Brazil or for investors residing in that country.
Losses can exceed deposits